Download Free Medical FDA Role in Regulation of Cannabis Products PowerPoint Presentation

FDA Role in Regulation of Cannabis Products PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : FDA Role in Regulation of Cannabis Products

Tags : FDA, Role in Regulation, Cannabis Products

Published on : Jul 01, 2020 | Views : 1596 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

FDA Role in Regulation of Cannabis Products NIDA February 2019 Sharon Lindan Mayl, J.D. Senior Advisor for Policy Office of Foods and Veterinary Medicine Food and Drug Administration Douglas C. Throckmorton, M.D. Deputy Director for Regulatory Programs CDER, FDA
Slide 2-

FDA’s Policy Interests 2 Protecting the public from harmful products Protecting the public from fraudulent products with unproven disease claims (which could result in patients foregoing proven treatments) Incentivizing rigorous scientific research to support beneficial therapies (through requiring NDAs) Protecting human subjects involved in research (through requiring INDs) Protecting the integrity of the conventional food supply and dietary supplements Respecting the “right to try” unapproved drugs for seriously ill patients
Slide 3-

FDA and Cannabis 3 Regulatory roles under the Federal Food, Drug & Cosmetic Act (FDCA): Scientific and regulatory support for research on potential therapeutic uses of cannabis Regulation of products (e.g., foods, drugs, cosmetics) from cannabis Enforcement actions as necessary against products made from cannabis or containing compounds found in the cannabis plant, particularly those that present human health risks FDA roles under the Controlled Substances Act (CSA): Assisting the Drug Enforcement Administration (DEA) on protocol registration for Schedule I drug research (Under 21 CFR 1301.18 and 1301.32) Conducts scientific and medical analysis (‘8-factor analysis’) to recommend appropriate controls under the CSA (working with NIDA) At DEA request Responding to citizen petitions New approved drug products with need for scheduling action
Slide 4-

Regulatory Landscape 4 Federal/state coordination is necessary: States DEA FDA USDA Others: SAMHSA, NIDA, ONDCP
Slide 5-

Intra-Agency Team 5 FDA has a cross-Agency team that works on cannabis issues: All product divisions represented as well as field inspectorate Policy Enforcement Outreach Interagency coordination – Federal, state, international
Slide 6-

The Farm Bill 6 Agriculture Improvement Act of 2018 (Farm Bill) changes some federal authorities related to the production and marketing of hemp. Establishes a state-USDA process and gives USDA the authority to issue federal regulations and guidelines concerning hemp production Hemp is defined as cannabis (Cannabis stativa L), and derivatives of cannabis, with extremely low (not more than 0.3 percent on a dry weight basis) concentrations of THC Removed hemp from the definition of marijuana in the Controlled Substances Act (CSA) Marijuana is still regulated by DEA under Schedule 1 of the CSA – Note: Epidiolex and certain future FDA approved CBD products have been classified as Schedule V
Slide 7-

The Farm Bill - FDA 7 FDA’s authorities under the FD&C Act and section 351 of the PHS Act were specifically preserved by the Farm Bill. Cannabis and cannabis-derived products are subject to the same authorities and requirements as FDA-regulated products containing any other substance.
Slide 8-

Overview of FDA Drug Authority 8 Under the FD&C Act, any product, including a cannabis product (hemp or otherwise), that is marketed with a claim of therapeutic benefit, or with any other disease claim, is considered to be a drug. A new drug must be approved by the FDA for its intended use before it may be introduced into interstate commerce.
Slide 9-

Drug Development from Cannabis Development of drugs has focused on using compounds in cannabis: CBD, THC Four products approved: Marinol (dronabinol) (1985): nausea from cancer chemotherapy. Schedule III Cesamet (nabilone) (1985 (2006)): nausea & neuropathic pain. Schedule II Syndros (dronabinol) (2016): nausea from cancer chemotherapy. Schedule II Epidiolex (CBD) (2018): for childhood seizures. Schedule V 9
Slide 10-

FDA Support for Drug Development from the Cannabis Plant 10 Regulatory programs and expediting pathways for important drug development Priority Review of NDAs, Fast Track Designation, Breakthrough Therapy Designation “FDA and Marijuana” web page includes links to Q&A page, guidance on initiating INDs or DMFs, contact points for Office of New Drugs’ review divisions, small business assistance, and links to NIDA Drug Supply Program and DEA registration site Updated final guidance in 2016, Botanical Drug Development, on the use of botanicals (e.g., cannabis) as sources for drugs Focus on quality manufacturing and controls during development
Slide 11-

FDA Support for Drug Development (cont’d) 11 Botanicals Team available to guide development of drugs from plants Can request Botanicals Team participation, to gain clarity on characterizing an investigational botanical drug to support proposed clinical study or NDA submission Controlled Substances Staff available to help with FDA- DEA interactions E.g., issues around abuse potential assessment requirements to support an NDA submission
Slide 12-

THC and CBD in Food: 301(ll) 12 CBD and THC cannot be added to foods under the FD&C Act regardless of whether the substances are hemp-derived. – Under section 301(ll) of the FD&C Act, it is prohibited to introduce or deliver for introduction into interstate commerce any food (including animal food or feed) to which has been added a substance which is an active ingredient in a drug product that has been approved under 21 U.S.C. § 355 (section 505 of the Act) or a drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Exception: If article was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted or, in the case of animal feed, that the drug is a new animal drug approved for use in feed and used according to the approved labeling. FDA has no evidence that this exception applies
Slide 13-

Other Applicable Regulatory Requirements for Foods 13 All foods are subject to a number of other regulatory requirements related to topics such as: Safety of ingredients Production controls Labeling
Slide 14-

Hemp Seed-Derived Ingredients 14 FDA completed the evaluation of three GRAS notices related to the use of hemp seed-derived food ingredients in December 2018. Hulled hemp seed, hemp seed protein, hemp seed oil Products have typical food uses FDA had no questions about the submitter’s conclusion that the ingredients were GRAS for the uses in the notice. These products can be legally marketed in human foods for these uses without food additive approval, provided they comply with all other requirements and do not make disease claims.
Slide 15-

THC and CBD in Dietary Supplements: 201(ff)(3)(B) 15 It is unlawful to market CBD and THC products as, or in, dietary supplements, regardless of whether the substances are hemp- derived. CBD and THC products are excluded from the definition of dietary supplements under the FD&C Act Under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, if a substance (such as THC or CBD) is an active ingredient in a drug product that has been approved under 21 U.S.C. § 355 (section 505 of the FD&C Act), or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement. Exception: If the substance was "marketed as" a dietary supplement or as a conventional food before the drug was approved or before the new drug investigations were authorized, as applicable. FDA has no evidence that this exception applies
Slide 16-

Cosmetics 16 No premarket approval for cosmetic products and ingredients, with the exception of color additives Must not be adulterated – Safe for consumers when used according to the directions in labeling and under customary/usual conditions of use Must not be misbranded If a topical product, including those that contain CBD, is intended to affect the structure or any function of the body, or to be used in the diagnosis, cure, mitigation, treatment, or prevention of disease, it is a drug, even if it is also a cosmetic (dual classification is common). New drugs must be approved
Slide 17-

Current FDA Warning Letters Related to CBD Products FDA has issued numerous WLs from 2015 to present Unapproved new drugs [§§201(p), 301(d), and 505(a)] Misbranded drugs [§§301(a) and 502(f)(1)] Illegally marketed food [§301(ll)] Illegally marketed supplements [§201(ff)(3)(B)] FDA posted lab results for dozens of CBD products cited in the warning letters. In many cases, the CBD content did not match the labeled claims and some products did not contain any CBD 17
Slide 18-

Challenges 18 Challenges include: hRanpgidinlyg-clegal frameworks at the federal, state, and local level Continually evolving market with many types of products Need for more data (e.g., safety) Need to support rigorous scientific research into therapeutic uses of products from cannabis Impact of Farm Bill on CBD for research Resources
Slide 19-

Commissioner Gottlieb Statement December 20, 2018 19 Affirming FDA’s commitment to protect and promote the public health with respect to these products, including enforcement action when needed Concern about unapproved drugs and about introduction into the food supply Soliciting input on how to make legal pathways for the lawful marketing of these products more efficient Taking steps to evaluate options for use in foods, including dietary supplements Intent to hold a public meeting for stakeholders to share experiences and challenges with these products – Including information related to safety https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm628988.htm
Slide 20-

FDA Website https://www.fda.gov/NewsEvents/PublicHealthFocus/ucm421168. htm 20
Slide 21-

Summary and Conclusions 21 FDA has a well-defined role to play in the regulation and development of products containing cannabis and cannabis-derived compounds FDA continues to focus on supporting scientific and rigorous testing and approval of drugs derived from cannabis FDA will solicit input on how to make legal pathways for the lawful marketing of these products more efficient FDA will continue to protect and promote the public health with respect to these products
Slide 22-

ppt slide no 22 content not found

User Presentation
Related Presentations

High-Performance Pharma Brand Plans - The 5 Pitfalls to avoid

By: MattB
Views: 2669

The Pharmaceutical Industry in Europe – Facts and Figure

By: MattB
Views: 1561

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2019

By: MattB
Views: 1538

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020 - Booklet 4.1

By: MattB
Views: 2336

Comparative Effectiveness Research (CER) and Patient-Centered Outcomes Research (PCOR)

By: MattB
Views: 2476

Pharmacology introduction

By: drdwayn
Views: 2614

Drug development planning through to late stage challenges

By: JenniferDwayne
Views: 2149

Quinolones Oxiquinolones Nitrofurans and Antiviral agents

By: drdwayn
Views: 1631

Digital Therapeutics and the Future of Pharma

By: anupma
Views: 4075

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020 - Booklet 4.3

By: MattB
Views: 2895

MattB

About : An experienced pharma professional managing sales, marketing and brand management of top global pharma products Presently leading a team of experts in the development and execution of pharma eCommerce strategies that support GSK products to HCP customers.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : United States of America
Website :

HEALTH A TO Z